Analysts at Ladenburg Thalmann turned incrementally bullish on Ignyta Inc RXDX after the company's therapy for the treatment of rare lung cancer showed encouraging results in a preliminary clinical trial among patients with a defective cancer-causing gene that is found in around 2 percent of all lung cancer instances. The firm's Kevin DeGeeter maintains a Buy rating on Ignyta's stockwith a price target boosted from $20.25 to $31. Read moreThe price will likely get back inside the rising channel. $RXDX, IGNYTA INC / D